167 related articles for article (PubMed ID: 19530227)
1. Synchrotron X-ray imaging reveals a correlation of tumor copper speciation with Clioquinol's anticancer activity.
Barrea RA; Chen D; Irving TC; Dou QP
J Cell Biochem; 2009 Sep; 108(1):96-105. PubMed ID: 19530227
[TBL] [Abstract][Full Text] [Related]
2. Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts.
Chen D; Cui QC; Yang H; Barrea RA; Sarkar FH; Sheng S; Yan B; Reddy GP; Dou QP
Cancer Res; 2007 Feb; 67(4):1636-44. PubMed ID: 17308104
[TBL] [Abstract][Full Text] [Related]
3. Tumor cellular proteasome inhibition and growth suppression by 8-hydroxyquinoline and clioquinol requires their capabilities to bind copper and transport copper into cells.
Zhai S; Yang L; Cui QC; Sun Y; Dou QP; Yan B
J Biol Inorg Chem; 2010 Feb; 15(2):259-69. PubMed ID: 19809836
[TBL] [Abstract][Full Text] [Related]
4. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
Daniel KG; Chen D; Orlu S; Cui QC; Miller FR; Dou QP
Breast Cancer Res; 2005; 7(6):R897-908. PubMed ID: 16280039
[TBL] [Abstract][Full Text] [Related]
5. Stoichiometry and conditional stability constants of Cu(II) or Zn(II) clioquinol complexes; implications for Alzheimer's and Huntington's disease therapy.
Ferrada E; Arancibia V; Loeb B; Norambuena E; Olea-Azar C; Huidobro-Toro JP
Neurotoxicology; 2007 May; 28(3):445-9. PubMed ID: 17382398
[TBL] [Abstract][Full Text] [Related]
6. Copper and clioquinol treatment in young APP transgenic and wild-type mice: effects on life expectancy, body weight, and metal-ion levels.
Schäfer S; Pajonk FG; Multhaup G; Bayer TA
J Mol Med (Berl); 2007 Apr; 85(4):405-13. PubMed ID: 17211610
[TBL] [Abstract][Full Text] [Related]
7. Clioquinol promotes cancer cell toxicity through tumor necrosis factor alpha release from macrophages.
Du T; Filiz G; Caragounis A; Crouch PJ; White AR
J Pharmacol Exp Ther; 2008 Jan; 324(1):360-7. PubMed ID: 17940196
[TBL] [Abstract][Full Text] [Related]
8. Development of a copper-clioquinol formulation suitable for intravenous use.
Wehbe M; Malhotra AK; Anantha M; Lo C; Dragowska WH; Dos Santos N; Bally MB
Drug Deliv Transl Res; 2018 Feb; 8(1):239-251. PubMed ID: 29247315
[TBL] [Abstract][Full Text] [Related]
9. Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells.
Chan-On W; Huyen NT; Songtawee N; Suwanjang W; Prachayasittikul S; Prachayasittikul V
Drug Des Devel Ther; 2015; 9():2033-47. PubMed ID: 25897210
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activity of the antibiotic clioquinol.
Ding WQ; Liu B; Vaught JL; Yamauchi H; Lind SE
Cancer Res; 2005 Apr; 65(8):3389-95. PubMed ID: 15833873
[TBL] [Abstract][Full Text] [Related]
11. Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): therapeutic indication for prostate cancer.
Cater MA; Haupt Y
Biochem J; 2011 Jun; 436(2):481-91. PubMed ID: 21426304
[TBL] [Abstract][Full Text] [Related]
12. A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.
Han J; Liu L; Yue X; Chang J; Shi W; Hua Y
Toxicol Appl Pharmacol; 2013 Dec; 273(3):477-83. PubMed ID: 24060341
[TBL] [Abstract][Full Text] [Related]
13. The metal chelating and chaperoning effects of clioquinol: insights from yeast studies.
Li C; Wang J; Zhou B
J Alzheimers Dis; 2010; 21(4):1249-62. PubMed ID: 21504115
[TBL] [Abstract][Full Text] [Related]
14. Clioquinol, a Cu(II)/Zn(II) chelator, inhibits both ubiquitination and asparagine hydroxylation of hypoxia-inducible factor-1alpha, leading to expression of vascular endothelial growth factor and erythropoietin in normoxic cells.
Choi SM; Choi KO; Park YK; Cho H; Yang EG; Park H
J Biol Chem; 2006 Nov; 281(45):34056-63. PubMed ID: 16973622
[TBL] [Abstract][Full Text] [Related]
15. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited.
Mancino AM; Hindo SS; Kochi A; Lim MH
Inorg Chem; 2009 Oct; 48(20):9596-8. PubMed ID: 19817493
[TBL] [Abstract][Full Text] [Related]
16. Copper-binding compounds as proteasome inhibitors and apoptosis inducers in human cancer.
Daniel KG; Chen D; Yan B; Dou QP
Front Biosci; 2007 Jan; 12():135-44. PubMed ID: 17127289
[TBL] [Abstract][Full Text] [Related]
17. Mutual stimulation of beta-amyloid fibrillogenesis by clioquinol and divalent metals.
Bolognin S; Zatta P; Drago D; Tognon G; Parnigotto PP; Ricchelli F
Neuromolecular Med; 2008; 10(4):322-32. PubMed ID: 18712494
[TBL] [Abstract][Full Text] [Related]
18. PBT2 acts through a different mechanism of action than other 8-hydroxyquinolines: an X-ray fluorescence imaging study.
Summers KL; Dolgova NV; Gagnon KB; Sopasis GJ; James AK; Lai B; Sylvain NJ; Harris HH; Nichol HK; George GN; Pickering IJ
Metallomics; 2020 Dec; 12(12):1979-1994. PubMed ID: 33169753
[TBL] [Abstract][Full Text] [Related]
19. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity.
White AR; Du T; Laughton KM; Volitakis I; Sharples RA; Xilinas ME; Hoke DE; Holsinger RM; Evin G; Cherny RA; Hill AF; Barnham KJ; Li QX; Bush AI; Masters CL
J Biol Chem; 2006 Jun; 281(26):17670-80. PubMed ID: 16648635
[TBL] [Abstract][Full Text] [Related]
20. Effect of substituent of terpyridines on the in vitro antioxidant, antitubercular, biocidal and fluorescence studies of copper(II) complexes with clioquinol.
Kharadi GJ
Spectrochim Acta A Mol Biomol Spectrosc; 2014 Jan; 117():662-8. PubMed ID: 24128919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
